100 results about "Lipid emulsion" patented technology

Glycopyrronium bromide, derivatives and/or isomers thereof in combination with one or more active substances selected from a list of substances as recited in the claims and/or in the form of a W/Si emulsion, an O/W gel, a soap gel stick, and/or a surfactant-containing cleansing formula, and corresponding cosmetic preparations, in particular deodorant/antiperspirant preparations.

The invention provides an alprostadil frozen-drying lipid emulsion and a preparation method thereof. The emulsion comprises the following compositions in percentage by mass: 0.0005-0.01% of alprostadil, 1-10% of oil for injection, 0.01-5% of an emulsifier, 0.02-2% of a stabilizer, 0-0.5% of an antioxidant, 1-20% of a freeze-drying protecting agent, and proper pH regulator and water for injection; the preparation method comprises the steps of: stirring alprostadil and oil for injection, and evenly mixing to obtain an oil phase; stirring freeze-drying protecting agent and water for injection to obtain a water phase; respectively the emulsifier, antioxidant and stabilizer into the water phase or the oil phase according to the solubility; mixing the water phase and the oil phase, carrying out high-speed stirring and dispersion, carrying out constant volume on the water for injection, regulating the pH value to obtain initial emulsion; transferring the initial emulsion into a high-pressure homogenizer for homogenizing for many times, then filtering, subpackaging, freeze-drying to obtain the alprostadil frozen-drying lipid emulsion. The alprostadil frozen-drying lipid emulsion is more stable and more uniform, the preparation technology and method can be simplified, and the economic efficiency can be improved.

Lipid emulsion compositions and methods of using such composition via intravenous infusion to reduce the bioavailability and toxicity of poisonous agents in the bloodstream.

The invention relates to a lipid emulsion with a low anisidine value, which contains oily constituents, water, an emulsifying agent and an osmotic pressure regulator, wherein the lipid emulsion contains a metal ion chelant but not an antioxidant. The content of the metal ion chelant is below 100mg/ml. The metal ion chelant is one or more of sodium calcium edentate, edetate disodium, edetate sodium and edetic acid. The invention relates to a method for preparing the lipid emulsion with the low anisidine value as well. According to the invention, in the process of preparing the lipid emulsion, other antioxidants are not needed to add, such as Vitamin E (VE), the antioxidation can be implemented only by using the metal ion chelant, and the low anisidine value can be greatly reduced. The low anisidine value of the lipid emulsion cannot be reduced by adding other antioxidants.

The present invention provides lipid emulsions and methods of intravenously administering lipid emulsions to treat systemic toxicity caused by foreign lipophilic and amphiphilic substances. In particular, methods are provided to treat cardiovascular impairment, such as cardiotoxicity, asystole and ischemia of the brain and heart, and neurological impairments, such as seizures and comas, caused by foreign lipophilic and amphiphilic substances, including cardiovascular impairment caused by local anesthetics, tricyclic antidepressants, sodium channel blockers, and calcium channel blockers.

The invention relates to a clevidipine butyrate structured lipid emulsion which comprises clevidipine butyrate, structured triglyceride, an emulsifier, an isotonic agent, a pH regulator, and injection water, wherein the weight volume percentage of clevidipine butyrate is 0.05-0.1% (w/v); the weight volume percentage of structured triglyceride is 5-30% (w/v); the weight volume percentage of the emulsifier is 1.0-2.0% (w/v); and the weight volume percentage of the isotonic agent is 1.0-5.0% (w/v).

The present invention relates to compositions and methods for the storage and consumption of a lipid emulsion. In particular, the present invention relates to the storage of an omega-3 lipid emulsion for consumption in a container under non-oxidizing conditions.

An alprostadil lipid emulsion for injection and a preparation method therefor. The lipid emulsion contains alprostadil, phosphatidylcholine, phosphatidylglycerol, oil for injection and a lyophilized protective agent. Based on 1 part by weight of the alprostadil, the content of the phosphatidylcholine is 1200 to 4000 parts by weight, the content of the phosphatidylglycerol is 12 to 120 parts by weight, the content of the oil for injection is 2000 to 20000 parts by weight, and the content of the lyophilized protective agent is 16000 to 60000 parts by weight.

The invention relates to an iodinated lipid emulsion vascular thrombosis material, a preparation method and an application thereof, and belongs to the technical field of vascular thrombosis materials used in medical appliance intervention. The iodinated lipid emulsion vascular thrombosis material includes, by mass, 20-80% of iodinated lipid emulsion, 15-75% of temperature sensitive nano-hydrogel and 0.04-3.0% of a gelator; on the basis of the mass of the iodinated lipid emulsion, the iodinated lipid emulsion includes, by mass, 50-90% of lipiodol, 0.1-0.6% of a co-surfactant and the balanced water. The vascular thrombosis material is low in viscosity and is excellent in capability of resisting blood scouring, can form firm and durable thrombosis, can be image-developed for long period, brings convenience to reexamination and diagnosis of patients at any time, has better curative effects and is safe and controllable.

The invention relates to a method for determining an anisidine value of lipid emulsion. The method comprises the following steps: extracting the lipid emulsion with ethyl acetate and drying the ethyl acetate phase by low-temperature vacuum rotation distillation to obtain a residue 1 as a sample; or adding hexyl hydride to dissolve the residue 1, carrying out extraction with acetonitrile, enabling the hexyl hydride phase for standby use, and drying the acetonitrile phase by low-temperature vacuum rotation distillation to obtain a residue 2; dissolving the residue 2 with alcohol, sequentially adding a sodium hydrogen sulfite solution and ethyl acetate, carrying out extraction with water, carrying out extraction with ethyl acetate after adding hydrochloric acid in the water phase, combining the ethyl acetate phase with the hexyl hydride phase, and carrying out low-temperature vacuum rotation distillation for drying to obtain a residue 3 as a sample. According to the method for determining the anisidine value of the lipid emulsion, the interference to the detection result resulting from high-temperature operation and ultraviolet absorption of a main drug is effectively avoided; and the method is especially applicable to determination of the anisidine value of the lipid emulsion with the main drug having ultraviolet absorption at the wavelength of 350nm.

The invention relates to a lipid emulsion of magnolol and a preparation method thereof. According to the lipid emulsion of the magnolol and the preparation method thereof, the problem of poor water-solubility of the magnolol can be effectively solved. The following technical proposal is that the lipid emulsion of the magnolol is prepared from the following raw materials by weight percentage: 0.01%-5% of magnolol, 2-30% of oil for injection, 0.1-20% of an emulsifier, 1-10% of an isoosmotic adjusting agent, 0.001-1% of a stabilizer, 0.001-3% of an antioxidant, 0.00001-0.5% of a pH regulator and the balance of water for injection. The lipid emulsion of the magnolol, provided by the invention, is scientific in formulation, simple in formula, reliable in quality, good in stability, high in drug loading capacity, stable in long-term storage and good in safety, thus being a great innovation on the pharmaceutic preparation.

A composition and method for early bloom thinning of fruit trees and controlling cracking, wherein the composition provides that glyceride type of lipids are effective compounds for bloom thinning of fruit trees and controlling cracking of fruits and the method comprises making an aqueous emulsion with these lipids as active ingredients and spraying the emulsion on fruit trees at appropriate phenophases for blossom thinning or fruit cracking control. The composition further provides that copper compounds act as blossom thinning agents but cause phytotoxicity to trees and a mixture of the said lipid emulsion and copper compounds displays higher thinning effect than each applied alone and does not cause phytotoxicity to trees.

The invention discloses an alprostadil medium-and-long-chain lipid emulsion for injection and a preparation method thereof, belonging to the technical field of biological medicines. The lipid emulsion is composed of the following components in parts by weight: 0.01-0.1 part of alprostadil, 10-100 parts of long-chain triglycerides, 10-100 parts of medium-chain triglycerides, 1-20 parts of phospholipids, 0.01-1 part of oleic acid, 5-20 parts of glycerol and 300-2500 parts of water for injection. The particle size of the lipid emulsion is 50-200 nm, the lipid emulsion has good stability while the pH value is 5.0-8.0, and the contents of degradation products including prostaglandin A1 and prostaglandin B1 of alprostadil measured by using an HPLC (High Performance Liquid Chromatography) method are respectively below 1%. Compared with traditional alprostadil long-chain lipid emulsions, aqueous-phase alprostadil is significantly decreased, so that the vascular stimulation is reduced, and the liver load is reduced, therefore, the lipid metabolism can be accelerated, and the triglyceride level of plasma can be reduced.

A lipid emulsion of astragaloside A is proportional prepared from astragaloside A, oil, surfactant, isotonic regulator, cosolvent and water for injection. Its preparing process is also disclosed.

The invention provides purple perilla seed oil lipid emulsion oral solution, a beverage and a manufacturing method thereof. The purple perilla seed oil lipid emulsion oral solution is prepared from refined purple perilla seed oil, refined lecithin, glycerin, sterile pure water, an antioxidant, a stabilizer, a pH regulator, flavorings, species and the like serving as raw materials. A manufacturing process comprises the following steps of: under the protection of nitrogen, heating the refined purple perilla seed oil and the refined lecithin to dissolve the mixture into oil phase liquid; mixing the glycerin, the antioxidant, the stabilizer, the flavorings, the spices and the sterile pure water and dissolving the solution into water phase liquid; adding the oil phase liquid into the strongly stirred water phase liquid slowly; shearing the solution to form primary emulsion at a high speed; regulating the pH value of the primary emulsion to be between 6.5 and 8.5 with a little pH regulator; emulsifying the primary emulsion with a high pressure homogenizer; filtering the solution with a microporous membrane filter; bottling and sealing the obtained solution; sterilizing the solution by microwave; and heating the solution for sterilization to obtain the purple perilla seed oil lipid emulsion oral solution which has 1 to 50 percent of the purple perilla seed oil. The purple perilla seed oil lipid emulsion oral solution is applicable to the field of healthy food; the purple perilla seed oil lipid emulsion oral solution having a high concentration of 5 to 50 percent can serve as a functionally nutritious health beverage; and the purple perilla seed oil lipid emulsion oral solution having a low concentration of 1 to 20 percent can serve as drinks for dinner and popular drinks.

The invention relates to a nanometer lipid emulsion which comprises a drug, oil, an emulgator and water, wherein the solubility of the drug is 0-0.0005g/ml and the drug is difficult to dissolve in water. The emulsion is clear and is capable of reducing the drug degradation and the emulsion droplet agglutination caused by ultrahigh pressure and high temperature. The drug is capable of being stably packed in the emulsion droplet, so that the toxic or side effect of the drug is reduced.

The invention discloses a phospholipid complex of natural Baikal skullcap root active ingredients and a preparation method thereof. The natural Baikal skullcap root active ingredients mean an active fraction (the baicalein content is more than 50 percent) or an active ingredient (the baicalein content is more than 90 percent) of baicalein extracted and separated from Baikal skullcap roots serving as a Chinese medicament and an active fraction (the wogomin content is more than 50 percent) or an active ingredient (the wogomin content is more than 90 percent) of wogomin. The water solubility and lipid solubility of the natural Baikal skullcap root active ingredients are poor, the dissolubility of the active ingredients is increased along with rise of the pH value of a solution, and the active ingredients are easily chemically degraded under an alkali condition. Due to the insufficiency of the physical and chemical properties of the natural Baikal skullcap root active ingredients, the active ingredients cannot be prepared into injection, and the bioavailability is low after the active ingredients are orally taken. Through a phospholipid complex technology, the water dispersibility and lipophilic property of the Baikal skullcap root active ingredients are obviously improved, and then the Baikal skullcap root active ingredients can be prepared into high-bioavailability oral preparation, freeze-dried injection or lipid emulsion to meet the requirement for injection or mucosa administration.

The invention provides lipid-emulsion eye drops with dexamethasone. The lipid-emulsion eye drops are in an oil-in-water sub-micro emulsion system; grease in the emulsion drops is coated with lipid nano particles formed by lipid carriers and the dexamethasone. The invention aims at providing the lipid-emulsion eye drops with the dexamethasone and a preparation method thereof so as to increase tissue distribution in the eyes, promote permeation into the eyes and further achieve the purposes of safely and effectively treating intraocular diseases and fundus oculi diseases.

The present invention relates to the obesity-curative or obesity-preventive effect of a Polygonum cuspidatum butanol fraction and a Polygonum cuspidatum ethylacetate fraction, and more particularly, to a pharmaceutical composition and a functional food for treating obesity, the pharmaceutical composition and the functional food comprising a Polygonum cuspidatum butanol fraction (POCU-1b) and an ethylacetate fraction as active ingredients, wherein the Polygonum cuspidatum butanol fraction and the ethylacetate fraction inhibit effectively the activity of pancreatic lipase, an important enzyme involving in fat absorption in a living body, and have excellent inhibitory effect on fat absorption in the short term fat absorption-inhibitory animal experiments using lipid emulsions.

The invention provides a method for detecting an alprostadil freeze-dried lipid emulsion. The method comprises the steps: 1) adding water to the alprostadil freeze-dried lipid emulsion, and re-dissolving to obtain a sample aqueous solution; 2) demulsifying the sample aqueous solution obtained in the step 1) with a demulsifier, to obtain a demulsified sample solution, wherein the volume ratio (ml:ml) of the demulsifier to the sample aqueous solution is 5:1-5:6; and 3) determining the contents of alprostadil and prostaglandin A1 in the demulsified sample solution obtained in the step 2) by high performance liquid chromatography, wherein the demulsifier is composed of an organic solvent A and an organic solvent B, the organic solvent A is selected from the group consisting of alcohols, and the organic solvent B is selected from the group consisting of alkanes or tetrahydrofuran. The method for detecting the alprostadil freeze-dried lipid emulsion has the advantages of high recovery rate and accurate measurement results, enhances quality detection standards of the alprostadil freeze-dried lipid emulsion, reinforces the quality controllability of drugs, thereby ensuring the effectiveness and the safety of clinical medication.

The invention discloses a tacrolimus lipid emulsion for injection, and the tacrolimus lipid emulsion contains tacrolimus, an oily solvent for injection, a surfactant, amphiphilic block copolymers, an osmotic pressure regulator for injection, an antioxidant and a stabilizer. In addition, the invention also discloses a preparation method of the lipid emulsion. The tacrolimus lipid emulsion is capable of effectively increasing the chemical stability of the medicines; most of medicines in the tacrolimus lipid emulsion are distributed in an oil phase or an oil-water interface; and the medicines are prevented from directly contacting water, are solubilized into the oil phase, and are isolated, so that the medicine dosage of the water phase is reduced, the hydrolysis amount of the medicines is greatly reduced, and the stability on the medicines is greatly improved. The tacrolimus lipid emulsion for injection disclosed by the invention can be used for wrapping a part of medicines into the oil phase or an interfacial film, and preventing the medicines from directly contacting body fluid, so that the local and vascular stimulation which can be generated by the medicines is reduced.

The invention relates to fat emulsions, particularly to a use of high-concentration glycerol in freeze-thaw resistant emulsions and a free-thaw resistant emulsion thereof. The said high-concentration glycerol is the glycerol that is greater than or equal to 3 w/v % in the emulsion composition. The maximum percentage of the glycerol in the emulsion is 50 w/v %. When the percentage of the oil in the emulsion is 2%-30 w/v %, the glycerol is more than or equal to ⅓ of the oil in the emulsion. The invention comprises a drug-contained emulsion through including drugs. Compared with prior arts, the invention provides a freeze-thaw resistant emulsion which tolerates the low-temperature freeze-thaw experiments, avoiding the pharmaceutical stability issues due to the temperature changes during the emulsion transport, storage and utilization, ensuring medicine quality, meanwhile it drastically reduces the requirements of the transport and storage conditions as well as the medicine costs.